Successful conservative management of pelvic lytic lesion in a child with Burkitt's Lymphoma: A rare case report

Abstract

Background: Burkitt's Lymphoma (BL) can produce various clinical presentations and imaging appearances, according to the predilection of the different subtypes for certain sites. The gold standard treatment for BL remains the Magrath protocol as modified by the UK Lymphoma Group, as Cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate (CODOX-M)/ifosfamide, etoposide, and high-dose cytarabine (IVAC) is an alternating non-cross-resistant regimen. Rituximab is now routinely used in BL treatment based on its strong CD20 expression. Case report: We present a case of an 11-year-old female with Burkitt Lymphoma in the Pelvis. The patient was managed conservatively by 4 cycles of R-CODOX-M/R-IVAC for complete recovery of a pelvic lytic lesion. After the completion of chemotherapy, the patient got drastic clinical improvement with a massive decrease in the size of the swelling. Conclusion: To conclude Pelvic Lytic lesion with biopsy and IHC proven Burkitt Lymphoma, can be managed conservatively without surgery with adequate histology-based chemotherapy regimen. Level of evidence: Level V.

Keywords

• Lytic pelvic defect
• Burkitt's lymphoma
• Chemotherapy
• CODOX-M/IVAC
• Case report